Telomeres and Telomerase

The end-replication problem occurs when DNA replication machinery reaches chromosome ends. Removal of the final primer at the 5' end leaves a 3' overhang of single-stranded telomeric DNA that cannot be copied because there is no complementary DNA template for the primer. This results in gradual telomere shortening with each cell division.

Telomerase is a ribonucleoprotein enzyme composed of RNA and protein components. The RNA component contains a template sequence for telomere repeats, while the protein component, a reverse transcriptase, extends telomere DNA six nucleotides at a time using this RNA template. Telomerase then translocates and repeats this process, adding new telomere repeats before DNA polymerase completes replication.

Human telomeres are protective chromosome ends composed of repeating six-nucleotide guanine-rich sequences, specifically TTAGGG. Each human chromosome contains approximately 1,300 to 2,500 telomere repeats. These repeating sequences form a buffer zone that protects chromosome ends from degradation and inappropriate DNA repair activation.

Shelterin is a six-subunit protein complex that binds to double-stranded telomeric DNA and the 3' overhang remaining after primer removal. This complex loops back and inserts into upstream DNA, forming a displacement loop or D-loop. The resulting T-loop structure anchors the telomere end in place, protecting the chromosome from degradation, end-to-end fusion, and inappropriate DNA repair activation.

Replicative senescence is the arrest of cell proliferation caused by progressive telomere shortening with each cell division. Without telomerase-mediated synthesis of new telomere repeats, telomeres eventually become too short to protect chromosome ends, triggering senescence. Telomerase expression can increase cell lifespan and allow continuous proliferation, a characteristic feature of cancer cells.

Telomerase activity has been observed in almost 90% of cancer cells, making telomerase a major target for cancer research and treatment development. By reactivating telomerase, cancer cells can bypass replicative senescence and proliferate indefinitely. Understanding telomerase function in cancer cells is crucial for developing new therapeutic strategies to limit tumor growth.

Telomerase contains two essential components: telomerase RNA component (TERC) and telomerase reverse transcriptase (TERT). The TERC provides a template nucleotide sequence for synthesizing telomeric repeats, while TERT uses this template to synthesize short telomere repeats. Together, these components enable telomerase to extend telomeres and compensate for DNA lost during the leading strand and lagging strand synthesis process.